Early Notification and Brand Change REVISED Temozolomide Capsules
As advised via PHARMAC Tender Results of 29 March 2019 there is to be a change in the listing and future sole supply of Temozolomide Capsules.
Please refer to our original notification of 29 March 2019 for original timings as all but 5 mg will now been listed from 1 October 2019 to ensure ongoing supply. (Only the listing date changes)
New listing from 1 October 2019
Temaccord Caps 20 mg 5 capsule bottle pack Pharmacode 2388251 Schedule price $16.38
Temaccord Caps 100 mg 5 capsule bottle pack Pharmacode 2388243 Schedule price $35.98
Temaccord Caps 140 mg 5 capsule bottle pack Pharmacode 2566044 Schedule price $50.12
Temaccord Caps 250 mg 5 capsule bottle pack Pharmacode 2388235 Schedule price $86.34
Incumbent brand and DELISTED 1 May 2020
Temozolomide Orion Caps 20 mg 5 capsule bottle pack Pharmacode 2505959 Schedule price $18.30
Temozolomide-Apo Cap 20 mg 5 capsules per bottle pack Pharmacode 2572311 Schedule price $18.30
Temizole Caps 20 mg 5 capsule bottle pack S29 Pharmacode 2527170 Schedule price $96.80
Temozolomide Orion Caps 100 mg 5 capsule bottle pack Pharmacode 2505967 Schedule price $40.20
Temozolomide-Apo Caps 100 mg 5 capsule bottle pack Pharmacode 2572338 Schedule price $40.20
Temozolomide Orion Caps 140 mg 5 capsule bottle pack Pharmacode 2527162 Schedule price $56.00
Temozolomide Orion Caps 250 mg 5 capsule bottle pack Pharmacode 2505975 Schedule price $96.80
Reference pricing will not apply.
HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 May 2020.
Brand Switch Fee not in notification.
As of the date of this notification ProPharma / PWR cannot accept Temozolomide Orion (all strengths) for credit under any circumstances.
From 1 October 2019 community pharmacies dispensing Temozolomide Capsules (other than 5 mg)will need to support patients changing to the new brand and manage stock during the transition.
We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.
You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 May 2020. Failure to do so may prove costly.
Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.
ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both products listed and fully funded until the commencement of the sole supply 1 May 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change , however wholesalers and pharmacy do not need to experience potential losses during the transition period.
Together we can make this a seamless and painless transition.
We thank you in anticipation of your ongoing support.